Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 22, 2026Cardiology in Review

Oral step-down therapy yields similar rates of death, relapse, embolic events, and unplanned cardiac surgery compared with prolonged IV therapy, while substantially reducing hospital length of stay and line-related complications.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does transition to dual oral antibiotic regimens yield similar clinical outcomes compared to prolonged intravenous antibiotic therapy in clinically stable adults with infective endocarditis?

Population

Adults with infective endocarditis who are clinically stable after at least 10 days of effective IV treatment

Comparison

Transition to dual oral antibiotic regimens with… vs Prolonged intravenous antibiotic therapy

Design

Review

Authors

SKSaeedreza KhatamiMFMohammadsadegh FaghihiMTMahshid Talebi‐Taher

Discussion

Loading...

Member takes

Overview

May support early oral transition in selected stable IE patients; leaves open standardized implementation protocols.

Structured PICO

Does transition to dual oral antibiotic regimens yield similar clinical outcomes compared to prolonged intravenous antibiotic therapy in clinically stable adults with infective endocarditis?

P
Population
Adults with infective endocarditis (left-sided native or prosthetic valve) who are clinically stable (afebrile, hemodynamically stable, negative blood cultures, no uncontrolled infection on imaging) after at least 10 days of effective IV treatment
I
Intervention
Transition to dual oral antibiotic regimens with high bioavailability and pathogen-directed activity
C
Comparator
Prolonged intravenous (IV) antibiotic therapy (4-6 weeks)
O
Outcome
Rates of death, relapse, embolic events, and unplanned cardiac surgeryhard clinical

Partial oral antibiotic therapy is a safe and effective step-down strategy for selected, clinically stable patients with infective endocarditis, reducing hospital stay and IV-related complications.

Limitations

  • Data in people who inject drugs, those with multidrug-resistant pathogens, or severe heart failure remain limited
  • Robust pharmacokinetic validation of some oral β-lactam-based combinations is still needed

Cite This Study

Khatami et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff3ecd674f7c03778cdd1https://doi.org/10.1097/crd.0000000000001233
View Full Paper
Ask AI
Bookmark
Share